Abstract: Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.

Abstract: Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological equipment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.

Abstract: Pharmaceutical compositions comprising a pharmacologically active polypeptide and a pharmacologically or veterinarily acceptable amphipathic, non-cross-linked linear, branched or graft block copolymer, which has a minimum weight average molecular weight of 5,000, in which the hydrophobic component is biodegradable and the hydrophilic component may or may not be biodegradable, the composition being capable of absorbing water to form a hydrogel when placed in an aqueous, physiological-type environment; copolymers suitable for use in said compositions; and method for the manufacture of such copolymers.

Abstract: A pharmaceutically or veterinarily acceptable amphipathic, non-cross linked linear, branched or graft block copolymer, which has a minimum weight average molecular-weight of 1000, in which the hydrophobic component is biodegradable or hydrolytically unstable under normal physiological conditions, and the hydrophilic component may or may not be biodegradable or hydrolytically unstable under such conditions, and which copolymer is self-dispersible in water; together with mixtures of such a copolymer and a drug, which may be water-soluble or water-insoluble, which mixtures are self-dispersible in waterf; and processes for the manufacture of such copolymers and such mixtures.

Abstract: A process for the manufacture of polyesters, especially polylactides or poly(lactide-co-glycolide) of specified low-medium molecular weight, by controlled hydrolysis of a higher molecular weight polyester.

Abstract: Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.

Abstract: A pharmaceutically or veterinarily acceptable amphipathic, non-cross linked linear, branched or graft block copolymer, which has a minimum weight average molecular-weight of 1000, in which the hydrophobic component is biodegradable or hydrolytically unstable under normal physiological conditions, and the hydrophilic component may or may not be biodegradable or hydrolytically unstable under such conditions, and which copolymer is self-dispersible in water; together with mixtures of such a copolymer and a drug, which may be water-soluble of water-insoluble, which mixtures are self-dispersible in water; and processes for the manufacture of such copolymers and such mixtures.

Abstract: This invention relates to the use of a bisbiguanide compound of the formula:R.sup.1 R.sup.2 N.C(:NH)N:C(NH.sub.2)N--A--N.C(NH.sub.2):N.C(:NH)NR.sup.3 R.sup.4 Iwherein either:(i) R.sup.1 and R.sup.3, which may be the same or different, are each a phenyl radical which is substituted by alkyl, alkoxy, nitro or halogen, R.sup.2 and R.sup.4 are both hydrogen, and A is a 3-9C polymethylene diradical, wherein the polymethylene chain may be interrupted by oxygen atoms and/or by aromatic nuclei; or(ii) the bivalent bridge A is:(a) alkylene of from 2 to 12 carbon atoms having the valence bonds attached to different carbon atoms,(b) --(CH.sub.2).sub.m --X--(CH.sub.2).sub.n -- wherein m an n each represent an integer from 2 to 6 and X is O or S,(c) ##STR1## (d) ##STR2## wherein Z and Z.sup.1 are each alkylene of from 1 to 3 carbon atoms, (e) ##STR3## wherein Q is --O--, --S--, --SO-- or --SO.sub.2 --, (f) ##STR4## R.sup.1 and R.sup.

Abstract: This invention relates to the use of polymeric biguanides as topical contraceptive agents, which operate both by rendering vaginal mucus impenetrable to sperm, or by a direct spermicidal action.

Abstract: Pharmaceutical compositions comprising a pharmacologically active polypeptide and a pharmacologically or veterinarily acceptable amphipathic, non-cross-linked linear, branched or graft block copolymer, which has a minimum weight average molecular weight of 5,000, in which the hydrophobic component is biodegradable and the hydrophilic component may or may not be biodegradable, the composition being capable of absorbing water to form a hydrogel when placed in an aqueous, physiological-type environment; copolymers suitable for use in said compositions; and method for the manufacture of such copolymers.

Abstract: A sustained release delivery means comprising a biologically active agent and a hydrophilic linear block poly oxyalkylene- polyurethane copolymer.

Abstract: Sustained release delivery means comprising (i) a biologically active agent, (ii) a linear hydrophilic block polyoxyalkylene-polyurethane copolymer, and (iii) optionally containing a buffer. Included among the biologically active agents are abortifacient compounds.